Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bidirectional interplay between gut and liver in inflammatory bowel disease and hepatobiliary conditions.

Clinical and experimental medicine·2026
Same author

Comparing the types of haemochromatosis- from genetics to clinics.

European journal of human genetics : EJHG·2026
Same author

University students' preferences of learning modes post COVID-19-associated lockdowns: In-person, online, and blended.

PloS one·2024
Same author

Role of zinc in health and disease.

Clinical and experimental medicine·2024
Same author

Iron-Related Genes and Proteins in Mesenchymal Stem Cell Detection and Therapy.

Stem cell reviews and reports·2023
Same author

Iron and iron-related proteins in alcohol consumers: cellular and clinical aspects.

Journal of molecular medicine (Berlin, Germany)·2022

Related Experiment Video

Updated: Oct 1, 2025

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.5K

Hepcidin in hepatocellular carcinoma.

Jonathan H Joachim1, Kosha J Mehta2

  • 1GKT School of Medical Education, Faculty of Life Sciences and Medicine, King's College London, London, UK.

British Journal of Cancer
|March 10, 2022
PubMed
Summary

Hepcidin, the iron hormone, is involved in hepatocellular carcinoma (HCC) progression. Reduced hepcidin levels in HCC patients may drive cancer growth and increase risk, highlighting its diagnostic and therapeutic potential.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.1K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.4K

Related Experiment Videos

Last Updated: Oct 1, 2025

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.5K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.1K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.4K

Area of Science:

  • Hepatocellular carcinoma (HCC) research
  • Iron metabolism and cancer
  • Molecular mechanisms of cancer progression

Background:

  • Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality.
  • Elevated iron levels are linked to increased HCC risk.
  • Hepcidin, a key iron-regulating hormone, plays a complex role in HCC pathology, often showing reduced levels in patients.

Purpose of the Study:

  • To review the role of hepcidin in hepatocellular carcinoma (HCC).
  • To explore mechanisms regulating hepcidin levels in HCC.
  • To discuss the implications of hepcidin dysregulation for HCC diagnosis, prognosis, and treatment.

Main Methods:

  • Review of scientific literature on hepcidin and HCC.
  • Analysis of molecular mechanisms underlying hepcidin regulation in HCC.
  • Discussion of the functional consequences of hepcidin downregulation in HCC.

Main Results:

  • HCC patients often exhibit lower hepcidin levels compared to other cancers.
  • Mechanisms contributing to hepcidin reduction include downregulation of HAMP, TfR2, HJV, ALK2, circ_0004913, and inactivation of RUNX3, alongside upregulation of matriptase-2, GDF15, and TP53 mutations.
  • Hepcidin downregulation promotes HCC proliferation via CDK1/STAT3 activation and increases HCC risk by reducing protection against hepatic stellate cell activation.

Conclusions:

  • Hepcidin dysregulation is a significant factor in HCC development and progression.
  • Understanding the hepcidin-ferroportin axis offers potential diagnostic and therapeutic targets for HCC.
  • Targeting hepcidin pathways may provide novel strategies for HCC management.